MRLB-223

Overview

MRLB-223 is a preferential HDAC1 and HDAC2 inhibitor with activity against tumor cells.MRLB-223 induces histone hyperacetylation, intrinsic apoptotic pathway activation, tumor cell apoptosis , Hsp90 hyperacetylation, and caspase-dependent Bcr-Abl degradation.MRLB-223 mediates p53 -independent tumor cell death, with activity suppressed by Bcl-2 overexpression, and kills Bcr-Abl -expressing myeloid cells.MRLB-223 exerts effects in mice bearing Eμ-myc lymphomas.MRLB-223 can be used for the research of Eμ-myc lymphoma.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > HSP | Products > Signaling Pathways > HDAC | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Bcr-Abl

Product Information

• Catalog No.: HY-124792
• CAS No.: 937727-03-2
• Molecular Formula: C23H23N5O3S
• Molecular Weight: 449.53
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source